EASL HFE Hemochromatosis 2011. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010 Jul;53(1):3-22. PMID:
20471131
AASLD Hemochromatosis 2011. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology
2011 Jul;54(1):328-43. doi: 10.1002/hep.24330. PMID: 21452290
Hepatite (B e C)
EASL Clinical guidelines HBV 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85.
doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. PMID:
22436845
EASL Clinical guidelines HCV 2011. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011 Aug;55(2):245-64. doi: 10.1016/j.jhep.2011.02.023.
Epub 2011 Mar 1. PMID:21371579
AASLD Diagnosis of Hepatitis C 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759. PMID:
19330875
Adams, P. C., Reboussin, D. M., Barton, J. C., McLaren, C. E., Eckfeldt, J. H., McLaren, G. D., et al. (2005). Hemochromatosis and iron-overload screening in a racially diverse
population. N Engl J Med, 352(17), 1769-1778.
Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., et al. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the
International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120(16), 1640-1645.
Altés, A., Alústiza, J. M., Arrizabalaga, B., González, F. A., Matute, F., Remacha, A., et al. (2012). Utilidad de la resonancia magnética en el
diagnóstico de la sobrecarga férrica. . Barcelona: Novartis Farmacéutica, SA
Altés, A., Remacha, A. F., Sureda, A., Martino, R., Briones, J., Brunet, S., et al. (2003). Patients with biochemical iron overload: causes and characteristics of a cohort
of 150 cases. Ann Hematol, 82(2), 127-130.
Allen, K. J., Bertalli, N. A., Osborne, N. J., Constantine, C. C., Delatycki, M. B., Nisselle, A. E., et al. (2010). HFE Cys282Tyr homozygotes with serum ferritin concentrations
below 1000 microg/L are at low risk of hemochromatosis. Hepatology, 52(3), 925-933.
Bacon, B. R., Adams, P. C., Kowdley, K. V., Powell, L. W., & Tavill, A. S. (2011). Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association
for the Study of Liver Diseases. Hepatology, 54(1), 328-343.
Balwani, M., & Desnick, R. J. (2012). The porphyrias: advances in diagnosis and treatment. Blood, 120(23), 4496-4504.
Beaton, M. D., & Adams, P. C. (2012). Treatment of hyperferritinemia. Ann Hepatol, 11(3), 294-300.
Brissot, P., Bardou-Jacquet, E., Jouanolle, A. M., & Loreal, O. (2011). Iron disorders of genetic origin: a changing world. Trends Mol Med, 17(12), 707-713.
Caballeria, J., & Parés, A. (2012). Hepatopatías alcohólicas In Farreras-Rozman (Ed.), Medicina Interna (XVII ed., pp. 326). Barcelona: Elsevier.
Camaschella, C., Roetto, A., Cali, A., De Gobbi, M., Garozzo, G., Carella, M., et al. (2000). The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet,
25(1), 14-15.
Cazzola, M., Bergamaschi, G., Tonon, L., Arbustini, E., Grasso, M., Vercesi, E., et al. (1997). Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and
specific mutations in the iron-responsive element of ferritin light-chain mRNA. Blood, 90(2), 814-821.
Chang, T. P., & Rangan, C. (2011). Iron poisoning: a literature-based review of epidemiology, diagnosis, and management. Pediatr Emerg Care, 27(10), 978-985.
Crook, M.A. (2012). Hyperferritinemia; laboratory implications. Ann Clin Biochem, 49(Pt3),211-213.
Desai, T. K., Jamil, L. H., Balasubramaniam, M., Koff, R., & Bonkovsky, H. L. (2008). Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C:
a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci, 53(3), 815-822.
Díez-Sáez, C., Esteban-López, J., & Ayala-Curiel, J. (2003). Intoxicación por hierro y otros metales. In Mintegui S. Grupo de Trabajo de Intoxicaciones.
Manual de intoxicaciones en pediatría. Madrid: Ediciones Ergon SA.
EASL clinical practice guidelines for HFE hemochromatosis. (2010). J Hepatol, 53(1), 3-22.
Fontana, R. J., Israel, J., LeClair, P., Banner, B. F., Tortorelli, K., Grace, N., et al. (2000). Iron reduction before and during interferon therapy of chronic hepatitis C:
results of a multicenter, randomized, controlled trial. Hepatology, 31(3), 730-736.
Freixenet, N., Moreno-Rosel, M. S., Barcelo, M. J., Serrano, A., Paya, M., Crespo, L., et al. (2010). Detection of hereditary hemochromatosis and biochemical iron overload in
primary care: a multicenter case finding study in Spain. Am J Hematol, 85(4), 294-296.
Gentile, I., Viola, C., Paesano, L., D'Onofrio, M., D'Agostino, E., Cerini, R., et al. (2009). Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial.
J Clin Apher, 24(5), 190-196.
Gimferrer, E., Úbeda, J., Royo, M. T., & Marigó, G. J. (1998). Importancia clínica de la hiperferritinemia Bio-Ferrum 3, 17-32.
Girelli, D., Olivieri, O., Gasparini, P., & Corrocher, R. (1996). Molecular basis for the hereditary hyperferritinemia-cataract syndrome. Blood, 87(11), 4912-4913.
Guyader, D., Jacquelinet, C., Moirand, R., Turlin, B., Mendler, M. H., Chaperon, J., et al. (1998). Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.
Gastroenterology, 115(4), 929-936.
Harrison-Findik, D. D. (2007). Role of alcohol in the regulation of iron metabolism. World J Gastroenterol, 13(37), 4925-4930.
Henter, J. I., Horne, A., Arico, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., et al. (2007). HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic
lymphohistiocytosis. Pediatr Blood Cancer, 48(2), 124-131.
Jacobs, A. (1984). Serum ferritin and malignant tumours. Med Oncol Tumor Pharmacother, 1(3), 149-156.
Kannengiesser, C., Jouanolle, A. M., Hetet, G., Mosser, A., Muzeau, F., Henry, D., et al. (2009). A new missense mutation in the L ferritin coding sequence associated with
elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica, 94(3), 335-339.
Kohgo, Y., Ohtake, T., Ikuta, K., Suzuki, Y., Torimoto, Y., & Kato, J. (2008). Dysregulation of systemic iron metabolism in alcoholic liver diseases. J Gastroenterol Hepatol,
23 Suppl 1, S78-81.
Kushner, I. (1982). The phenomenon of the acute phase response. Ann N Y Acad Sci, 389, 39-48.
Le Gac, G., & Ferec, C. (2005). The molecular genetics of haemochromatosis. Eur J Hum Genet, 13(11), 1172-1185.
Lin, T. F., Ferlic-Stark, L. L., Allen, C. E., Kozinetz, C. A., & McClain, K. L. (2011). Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a
prognostic variable for mortality. Pediatr Blood Cancer, 56(1), 154-155.
Ludwig, J., Batts, K. P., Moyer, T. P., Baldus, W. P., & Fairbanks, V. F. (1993). Liver biopsy diagnosis of homozygous hemochromatosis: a diagnostic algorithm. Mayo Clin Proc,
68(3), 263-267.
Luscieti, S., Tolle, G., Aranda, J., Campos, C. B., Risse, F., Moran, E., et al. (2013). Novel mutations in the ferritin-L iron-responsive element that only mildly impair IRP
binding cause hereditary hyperferritinemia cataract syndrome. Orphanet J Rare Dis, 8(1), 30.
Mateo-Gallego, R., Calmarza, P., Jarauta, E., Burillo, E., Cenarro, A., & Civeira, F. (2010). Serum ferritin is a major determinant of lipid phenotype in familial combined
hyperlipidemia and familial hypertriglyceridemia. Metabolism, 59(2), 154-158.
McGill, D. B., Rakela, J., Zinsmeister, A. R., & Ott, B. J. (1990). A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology, 99(5),
1396-1400.
Moirand, R., Mortaji, A. M., Loreal, O., Paillard, F., Brissot, P., & Deugnier, Y. (1997). A new syndrome of liver iron overload with normal transferrin saturation. Lancet,
349(9045), 95-97.
Morrison, E. D., Brandhagen, D. J., Phatak, P. D., Barton, J. C., Krawitt, E. L., El-Serag, H. B., et al. (2003). Serum ferritin level predicts advanced hepatic fibrosis among
U.S. patients with phenotypic hemochromatosis. Ann Intern Med, 138(8), 627-633.
Njajou, O. T., Vaessen, N., Joosse, M., Berghuis, B., van Dongen, J. W., Breuning, M. H., et al. (2001). A mutation in SLC11A3 is associated with autosomal dominant
hemochromatosis. Nat Genet, 28(3), 213-214.
Ogilvie, C., Fitzsimons, K., & Fitzsimons, E. J. (2010). Serum ferritin values in primary care: are high values overlooked? J Clin Pathol, 63(12), 1124-1126.
Olynyk, J. K., O'Neill, R., Britton, R. S., & Bacon, B. R. (1994). Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications.
Gastroenterology, 106(3), 674-677.
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L., Franchini, P. L., Dube, M. P., et al. (2004). Mutations in HFE2 cause iron overload in chromosome 1q-linked
juvenile hemochromatosis. Nat Genet, 36(1), 77-82.
Piccinino, F., Sagnelli, E., Pasquale, G., & Giusti, G. (1986). Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies.
J Hepatol, 2(2), 165-173.
Pietrangelo, A. (2004). Hereditary hemochromatosis--a new look at an old disease. N Engl J Med, 350(23), 2383-2397.
Pietrangelo, A. (2010). Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology, 139(2), 393-408, 408 e391-392.
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., et al. (2003). Mutant antimicrobial peptide hepcidin is associated with severe juvenile
hemochromatosis. Nat Genet, 33(1), 21-22.
Roy, C. N. (2010). Anemia of inflammation. Hematology Am Soc Hematol Educ Program, 2010, 276-280.
Ryan Caballes, F., Sendi, H., & Bonkovsky, H. L. (2012). Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int, 32(6), 880-893.
Saglini, V., & Brissot, P. (2012). [Hyperferritinemia--Algorithm]. Rev Med Suisse, 8(342), 1135-1137.
Tavill, A. S. (2001). Diagnosis and management of hemochromatosis. Hepatology, 33(5), 1321-1328.
Thurlow, V., Vadher, B., Bomford, A., DeLord, C., Kannengiesser, C., Beaumont, C., et al. (2012). Two novel mutations in the L ferritin coding sequence associated with
benign hyperferritinemia unmasked by glycosylated ferritin assay. Ann Clin Biochem, 49(Pt 3), 302-305.
Valenti, L., Fracanzani, A. L., Dongiovanni, P., Bugianesi, E., Marchesini, G., Manzini, P., et al. (2007). Iron depletion by phlebotomy improves insulin resistance in patients
with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol, 102(6), 1251-1258.
Waalen, J., Felitti, V. J., Gelbart, T., & Beutler, E. (2008). Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood, 111(7), 3373-3376.
Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M., & Torti, S. V. (2010). Serum ferritin: Past, present and future. Biochim Biophys Acta, 1800(8), 760-769.
Zacharski, L. R., Ornstein, D. L., Woloshin, S., & Schwartz, L. M. (2000). Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data.
Am Heart J, 140(1), 98-104.
Zanella, A., Gridelli, L., Berzuini, A., Colotti, M. T., Mozzi, F., Milani, S., et al. (1989). Sensitivity and predictive value of serum ferritin and free erythrocyte
protoporphyrin for iron deficiency. J Lab Clin Med, 113(1), 73-78.